Results 171 to 180 of about 6,337 (198)

New Data on Paxlovid Reported

AJN, American Journal of Nursing, 2022
According to this study: In a phase 2/phase 3 study of Paxlovid use in patients at standard risk for developing severe COVID-19, the primary end point of self-reported sustained alleviation of all symptoms for four consecutive days wasn't met.A nonsignificant ...
openaire   +2 more sources

Effectiveness of Paxlovid - a review

2023
AbstractPaxlovid is an oral treatment for mild to moderate COVID-19 cases with a high risk for severe course of the disease. For this review, we have performed a comprehensive literature review. We present a summary of currently available data on Paxlovid’s ability to reduce the risk of progressing to a severe disease state.
Sydney Paltra, Tim Conrad
openaire   +1 more source

Paxlovid as a potential treatment for long COVID

Expert Opinion on Pharmacotherapy, 2023
On 31 July 2023, the United States Department of Health and Human Services announced the formation of the Office of Long COVID Research and Practice and the United States National Institutes of Health opened enrollment for RECOVER-Vital, a randomized study to evaluate new treatment options for long Coronavirus (long COVID).The RECOVER Initiative is a ...
openaire   +2 more sources

Paxlovid‐associated dysgeusia

Oral Diseases, 2022
John K. Brooks, Julia H. Song, Ahmed S. Sultan   +2 more
openaire   +2 more sources

Nirmatrelvir-Ritonavir (Paxlovid)

Canadian Journal of Health Technologies
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the ...
openaire   +1 more source

Paxlovid Expiration Dates Extended

JAMA, 2022
openaire   +2 more sources

Inequity in Paxlovid Prescribing

JAMA, 2022
openaire   +2 more sources

Epidemiological Study of the Effectiveness of Paxlovid

Clinical Infectious Diseases, 2022
Hui-Yuan Chen, Renin Chang, James Cheng-Chung Wei   +2 more
openaire   +2 more sources

Paxlovid Drug Interaction Screening Checklist Updated

JAMA, 2022
openaire   +2 more sources

Paxlovid Prescribing Requires Pharmacy Workload Assessments

American Journal of Health-System Pharmacy, 2022
openaire   +2 more sources